Coley's toxins in perspective
The DOI matches its Crossref record; 6 of the 6 references it cites were found in a registry or an index.
Abstract
Despite initial hopes, the efficacy of tumour necrosis factor in treating cancer patients has been disappointing. But a more careful selection of patients, and more appropriate treatment, might be fruitful.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“However, in certain cases, injection of intratumoral bacteria or their antigens may conversely provide immunostimulatory effects, as demonstrated by Coley’s toxins and recent developments in bacterial cancer therapy (5, 105, 106).”
From The microbiome and human cancer (2021) · cites this paper as [5]
Citations
Cites
An endotoxin-induced serum factor that causes necrosis of tumors
Carswell, E. A., Old, L. J., Kassel, R. L., Green, S., Fiore, N., & Williamson, B. (1975) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.72.9.3666 · Cited by 4,532
Goetz, F. (2004) · Developmental & Comparative Immunology · doi:10.1016/j.dci.2003.09.008 · Cited by 301
Berendt, M. J., North, R. J., & Kirstein, D. P. (1978) · The Journal of Experimental Medicine · doi:10.1084/jem.148.6.1560 · Cited by 84
Prevalence of dysplasia and cancer of the cervix in a nationwide, planned parenthood population
Sadeghi, S. B., Sadeghi, A., & Robboy, S. J. (1988) · Cancer · doi:10.1002/1097-0142(19880601)61:11<2219::aid-cncr2820611116>3.0.co;2-d · Cited by 58
Demetri, G. D., Spriggs, D. R., Sherman, M., Arthur, K. A., Imamura, K., & Kufe, D. W. (1989) · Journal of Clinical Oncology · doi:10.1200/jco.1989.7.10.1545 · Cited by 57
Remarks upon the Effects Observed in the Use of Mixed Toxins (Coley) in Certain Cases of Sarcoma
Harmer, T. W. (1914) · New England Journal of Medicine · doi:10.1056/nejm191408131710701 · Cited by 4
Research works printed but not linked: 4
- Coley, W. B. Practitioner 83, 589–613 (1909).
- Nauts, H. C. et al. Can. Res. 6, 205–216 (1946).
- Tichatschek, E. et al. Can. Immun. Immunother. 27, 278–282 (1988).
- McIntosh, J. K. et al. Can. Res. 49, 1408–1414 (1989).
Cited by
Items 201–282 of 282
Paradigm Shifts in Perspective III: The Discovery of Tumor Necrosis Factor
Kaunitz, J. D. (2014) · Digestive Diseases and Sciences · doi:10.1007/s10620-014-3041-6 · Cited by 3
“Although the use of TNF in cancer immunotherapy has been mostly disappointing [5], anti-TNF ‘‘biologic’’ drugs have had powerful impact on the therapy of inflammatory bowel disease, demonstrating yet again that major therapeutic shifts can be decades or even centuries in the making and that they might arise from scien…”
BackgroundXAGE-1b Cancer/Testis Antigen Is a Potential Target for Immunotherapy in Prostate Cancer
Xie, C., & Wang, G. (2015) · Urologia Internationalis · doi:10.1159/000363333 · Cited by 3
Modeling Immune-Mediated Tumor Growth and Treatment
de Pillis, L. G., & Radunskaya, A. (2014) · Modeling and simulation in science, engineering & technology · doi:10.1007/978-1-4939-0458-7_7 · Cited by 3
“This treatment was successful enough to encourage other doctors to follow suit throughout the following decades [56].”
BackgroundDevelopments in anticancer vaccination: budding new adjuvants
Santos‐Sierra, S. (2019) · Biological Chemistry · doi:10.1515/hsz-2019-0383 · Cited by 5
Nitrogen Monoxide (Nitric Oxide): Bioinorganic Chemistry
Lancaster, J. R., & Giles, G. I. (2005) · Wiley eBooks · doi:10.1002/9781119951438.eibc0145 · Cited by 3
Albert, A., Badeti, S., Chen, L., Dongfang, L., & Donghong, C. (2019) · International Journal of Cancer and Clinical Research · doi:10.23937/2378-3419/1410127 · Cited by 2
Cancer and immunotherapy: An updated clinical review
Khajuria, A., & Kushte, S. S. (2023) · Santosh University Journal of Health Sciences · doi:10.4103/sujhs.sujhs_4_23 · Cited by 2
Establishment of immune suppression by cancer cells in the tumor microenvironment
Nishikawa, H. (2024) · Proceedings of the Japan Academy Series B · doi:10.2183/pjab.100.005 · Cited by 3
“23) – 25) In the early 20th century, P. Ehrlich postulated that cancers occur spontaneously in vivo and that the immune system is able to recognize and protect against them.”
BackgroundMcDowell, R. C., Booth, J. D., McGowan, A., Kołodziejczyk, W., Hill, G., Banerjee, S., Feng, M., & Капуста, К. (2024) · Cancers · doi:10.3390/cancers16132295 · Cited by 2
“…defenses to destroy cancerous cells. enhance the body’s defenses to destroy cancerous cells. origins of cancer immunotherapy date back to early 1891, when William Coley The origins of cancer immunotherapy date back to early 1891, when William Coley proposed to utilize the immune system for…”
BackgroundTripokin: A multi‐specific immunocytokine for cancer immunotherapy
Prodi, E., Corbellari, R., Ghezzi, L., Ciambellotti, S., Catastini, J. E., Rappuoli, M., Rotta, G., Sakic, I., Weiss, T., Weller, M., et al. (2024) · International Journal of Cancer · doi:10.1002/ijc.35145 · Cited by 2
“4,5 The promising antitumor effects of TNF were attributed to its potent impact on tumor vasculature and its ability to promote hemorrhagic necrosis.”
Memory T Cells, Recombinant Listeria monocytogenes, and Cancer Vaccines
Olagunju, A. S., Loza, M. L., Rocha, M. C., & Amarante-Mendes, G. P. (2025) · Frontiers in Bioscience-Landmark · doi:10.31083/fbl36329 · Cited by 3
Immunotherapy for HIV-associated non-Hodgkin's lymphoma
Newsom-Davis, T. E., Ahamed, E., & Bower, M. (2009) · Expert Opinion on Biological Therapy · doi:10.1517/14712590903183516 · Cited by 2
“He went on to stimulate systemic immunity against tumours using bacterial extracts from Streptococcus pyogenes and Serratia marcescens, ‘Coley’s toxin’; a significant number of the hundreds of patients treated achieved remission and even cure [2].”
BackgroundBiological Modulation of the Treg:Teff Ratio: From Immunosuppression to Immunoactivation
Yang, X., & Scott, M. D. (2020) · IntechOpen eBooks · doi:10.5772/intechopen.92038 · Cited by 2
The War on Cancer: A Report from the Front Lines
Melmed, G. M. (2006) · Baylor University Medical Center Proceedings · doi:10.1080/08998280.2006.11928194 · Cited by 2
“However, in the preantibiotic era, his patients experienced considerable complications from this treatment, and clinical interest in “Coley’s vaccine” diminished after his death (106, 107).”
BackgroundInfluence of Intestinal Flora on ICB Therapy for Colorectal Cancer
赵, 飞. (2024) · Advances in Clinical Medicine · doi:10.12677/acm.2024.14123181 · Cited by 2
Luo, Z., Xu, D., Wang, Z., Wu, L., Ou, C., & Ou, Z. (2026) · Genes & Diseases · doi:10.1016/j.gendis.2026.102270 · Cited by 1
Targeting the intratumoral microbiota to overcome cancer immunotherapy resistance
Tang, B., Jiang, T., Lin, Y. N., Zhang, W., Fan, H., Yang, M., Li, B., Liu, Y., Li, C., Xl, J., et al. (2026) · Interdisciplinary medicine · doi:10.1002/inmd.70155
Leffel, E. K., Twenhafel, N. A., & Whitehouse, C. A. (2008) · Journal of Infection · doi:10.1016/j.jinf.2008.04.008 · Cited by 1
Immunotherapeutic Strategies for Colon Cancer: Monoclonal Antibody Therapy
Thara, E., & Barzi, A. (2015) · Current Colorectal Cancer Reports · doi:10.1007/s11888-015-0260-y · Cited by 1
Cooper, M. A., & Caligiuri, M. A. (2003) · Elsevier eBooks · doi:10.1016/b978-012689663-3/50057-0 · Cited by 3
Can an Engineer Fix an Immune System?–Rethinking theoretical biology
Mattiussi, C. (2013) · Acta Biotheoretica · doi:10.1007/s10441-013-9180-x · Cited by 1
“…regression of cancer in the presence of infection (Hoption Cann et al. 2002) and the regressions observed following the injection of Coley’s toxin (Starnes 1992) and bacillus Calmette-Guérin (Terry 1975) are the consequence of the ensuing coincidental generation of danger signals at the SMM…”
BackgroundThe promise, progress, and challenges of in situ immunization agents in cancer immunotherapy
Giacalone, M. J. (2024) · Progress in molecular biology and translational science · doi:10.1016/bs.pmbts.2024.02.004 · Cited by 1
TIME Is Critical for Oncolytic Viral Therapies Against Solid Cancers
Kumar, V., & Stewart, J. H. (2024) · Interdisciplinary cancer research · doi:10.1007/16833_2024_440 · Cited by 1
Effects of talactoferrin alpha on lung adenoma prevention in A/J mice June 2, 2016.
Seabloom, D. E., Galbraith, A., Haynes, A. M., Fujita, A., Antonides, J., Wuertz, B. R. K., Steele, V. E., Ondrey, F. G., & Wattenberg, L. W. (2018) · PubMed Central · Cited by 1
Daenen, S. M. G. J., Huiges, W., Veenema, B., van der Waaij, D., & Halie, R. M. (1993) · Leukemia Research · doi:10.1016/0145-2126(93)90107-v · Cited by 1
Schlafen-11 and -9 are innate immune sensors for intracellular single-stranded DNAPreprint
Zhang, P., Hu, X., Li, Z., Liu, Q., Liu, L., Jin, Y., Liu, S., Zhao, X. H., Wang, J., Hao, D., et al. (2024) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2024.02.24.581893 · Cited by 1
Monitoring Antigen-specific T Cell Responses
Nagorsen, D., & Marincola, F. M. (2005) · Springer eBooks · doi:10.1007/1-4020-3623-x_1
“Later Coley (2) developed his famous toxin from gram-positive Streptococcus pyogenes and gram-negative Serratia marcescens and was relatively successful in treating sarcoma patients ( 3 ).”
BackgroundCastegren, M. (2011) · DiVA (Digitala Vetenskapliga Arkivet)
The Immunological Cause, Prevention, and Treatment of Tuberculosis
Stanford, J. L. (1998) · Springer eBooks · doi:10.1007/978-1-4615-5987-0_9
Montaner, B. (2001) · LA Referencia (Red Federada de Repositorios Institucionales de Publicaciones Científicas)
Catabolism and Tumor — Could a General Catabolic Reaction Be Useful in Treatment of Solid Tumors?
Giercksky, K. E., & Qvist, H. (1996) · Update in intensive care and emergency medicine · doi:10.1007/978-3-642-48801-6_17
Goto, S., KANEKO, T., & Egawa, K. (2004) · Japanese Journal of Complementary and Alternative Medicine · doi:10.1625/jcam.1.85
Lim, S. H., Zhang, Y., & Zhang, J. (2012)
InCVAX as a Novel In Situ Autologous Cancer Vaccine
Lam, S. S. K., Zhou, F., Hode, T., Nordquist, R., Alleruzzo, L., Raker, J., & Chen, W. R. (2015) · Asia Communications and Photonics Conference · doi:10.1364/acpc.2015.asu1i.2
Biological activity of lipopolysaccharides of gram-negative bacteria
Zdorovenko, E. L., Позур, В. К., & Kucherenko, N. E. (2000) · Biopolymers and Cell · doi:10.7124/bc.000550 · Cited by 1
Gosk, S. (2008) · bonndoc (University of Bonn)
Therapeutic brain cancer targeting by gene therapy and immunomodulation
Savelkoul, H. F. J., & Schijns, V. E. C. J. (2012)
Nanoparticulate Immunotherapy: An Intelligent Way to Tailor Make Our Defense System
Acharya, R., Saha, S., Ray, S., & Chakraborty, J. (2017) · Springer eBooks · doi:10.1007/978-981-10-3647-7_13
Predictors of Response to Immune Checkpoint Blockade
Andrews, M. C., & Wargo, J. A. (2017) · Springer eBooks · doi:10.1007/978-3-319-62431-0_31
Berinstein, N. L., & Spaner, D. (2008) · Elsevier eBooks · doi:10.1016/b978-1-4160-3611-1.50045-3
Potential Immunotherapy for Tuberculosis and Future Potential for HIV
Stanford, J. L., & Rook, G. A. W. (1997) · Springer eBooks · doi:10.1007/978-1-4899-3446-8_24
Remission and recurrence. What do to next?
Belciug, S. (2020) · Elsevier eBooks · doi:10.1016/b978-0-12-820201-2.00008-8
Cytokines and Inflammatory Arthritis
Wilson, A. G., & Duff, G. W. (1994) · Springer eBooks · doi:10.1007/978-94-011-1432-5_5 · Cited by 1
Agent-Based Modeling of Infected Cell Killing Mediated by Cytotoxic T-cells
Rastogi, A. (2021) · Digitale Bibliothek Braunschweig (Verbundzentrale Göttingen (VZG)) · doi:10.24355/dbbs.084-202106031104-0
Yang, X., Toyofuku, W. M., & Scott, M. D. (2021) · Archivum Immunologiae et Therapiae Experimentalis · doi:10.1007/s00005-021-00634-5
Markel, J. (2020) · The Research Repository @ WVU (West Virginia University) · doi:10.33915/etd.7770 · Cited by 1
Targeting Tumor-Induced Immunosuppression Using Conventional Cancer Therapeutics
Eriksson, E., Lövgren, T., & Loskog, A. (2021) · Medical Research Archives · doi:10.18103/mra.v9i12.2606
“William Coley used mixtures of live and inactivated bacteria as a treatment for sarcoma.(2,3) Unfortunately, this crude bacterial soup also put patients at risk for infection and further progress was on hold.”
MethodImproving immunotherapy for high grade glioma
Hunn, M. K. (2015) · Open Access Victoria University of Wellington | Te Herenga Waka (Figshare) · doi:10.26686/wgtn.17013347
Improving immunotherapy for high grade glioma
Hunn, M. K. (2015) · doi:10.26686/wgtn.17013347.v1
Nitrogen Monoxide (Nitric Oxide): Bioinorganic Chemistry
Lancaster, J. R., & Giles, G. I. (2005) · Wiley eBooks · doi:10.1002/0470862106.ia155
Kalyan, S., He, W., & Kabelitz, D. (2014) · Elsevier eBooks · doi:10.1016/b978-0-12-416721-6.00052-2
Kappauf, H. W., & Gallmeier, W. M. (2006) · Springer eBooks · doi:10.1007/3-540-31303-6_11
He, X. (2020) · IntechOpen eBooks · doi:10.5772/intechopen.87403
Yang, X., Toyofuku, W. M., & Scott, M. D. (2019) · Research Square · doi:10.21203/rs.2.18715/v1
Das, A., & Garg, S. (2022) · Elsevier eBooks · doi:10.1016/b978-0-323-96128-8.00003-1
The role of cellular immunity in the treatment of cancer
Στραβοκεφάλου, Β. (2023) · doi:10.12681/eadd/54076
The Changing Fortune of Cancer Immunotherapy
Marks, L. V. (2017) · Royal Society of Chemistry eBooks · doi:10.1039/bk9781782620846-00097
Haddox, C. L., Nathenson, M. J., Mazzola, E., Lin, J., Bagińska, J., Nau, A. N., Weirather, J. L., Choy, E., Mariño‐Enríquez, A., Morgan, J. A., et al. (2024) · doi:10.1158/1078-0432.25515976.v1
WITHDRAWN: Bacteria beneficially alter the tone of immune responses against tumors
Vitetta, L., & Clarke, S. J. (2024) · Elsevier eBooks · doi:10.1016/b978-0-443-14064-8.00008-4
The Emerging Role of the Microbiome in Carcinogenesis
Gates, T. J., Dietz, M. A., Martell, M., Balbo, S., Subramanian, S., & Staley, C. M. (2024) · Elsevier eBooks · doi:10.1016/b978-0-323-95488-4.00093-0
(2024) · Elsevier eBooks · doi:10.1016/b978-0-443-21798-2.16001-4
Bacteria beneficially alter the tone of immune responses against tumors
Vitetta, L., & Clarke, S. J. (2024) · Elsevier eBooks · doi:10.1016/b978-0-443-14064-8.90008-0
Targeting engineered bacteria to improve cancer immunotherapy
Dash, A., Bahuguna, S., & Das, J. K. (2024) · Elsevier eBooks · doi:10.1016/b978-0-443-13827-0.00004-4
Cancer Immunology and Immunotherapy
Wang, G.-R., Cao, L., Xu, Z., Liu, B., Wu, Q., & Bu, L. (2025) · Springer eBooks · doi:10.1007/978-981-96-3659-4_1 · Cited by 1
Mbodi, L., Adam, M. A., Marutha, T., Chatziioannou, A. A., & Dlamini, Z. (2025) · Elsevier eBooks · doi:10.1016/b978-0-443-45495-0.00008-5
Bhattacharjee, G., Girisa, S., Kunnumakkara, A. B., & Kundu, L. M. (2025) · Archives of Microbiology · doi:10.1007/s00203-025-04524-8 · Cited by 1
“…since the discovery of Coley’s toxin over a century ago, when Dr. William Coley developed a mixture of Streptococcus pyogenes and Serratia marcescens , a combination now known as “Coley’s Toxins”, to successfully treat patients with soft tissue sarcoma (Starnes 1992; Hop-tion Cann et al. 2003 ).”
Devil Facial Tumour Disease: In vivo studies in mice
Pinfold, T. L. (2014) · UTAS Research Repository · doi:10.25959/23242457
Bhattacharjee, G., Girisa, S., Kunnumakkara, A. B., & Kundu, L. M. (2025) · ChemistrySelect · doi:10.1002/slct.202503413
Körpertemperatur – was ist normal, was ist Fieber, wem nützt es?
Stange, R. (2026) · Zeitschrift für Komplementärmedizin · doi:10.1055/a-2765-8549
Lee, J., Kang, B., Moon, J. S., Um, T., Choi, J. E., Lee, M., Chae, Y. S., Lee, S. J., Lee, I. H., Lee, S. J., et al. (2026) · Cancers · doi:10.3390/cancers18060919 · Cited by 2
“Although immunotherapy for the treatment of cancers has been proposed for more than a century [1–3], breast cancer has been excluded because it has not been considered immunogenic.”
Optimisation de la réponse immune après traitement locorégional de tumeurs colorectales murines
Lemdani, K. (2018) · theses.fr (ABES) · doi:10.70675/ed125c40zec1cz40daz81afz1fca2f2f4139
Local Anti-CTLA4 Cancer Immunotherapy From Bench to Bedside
Tselikas, L. (2021) · theses.fr (ABES) · doi:10.70675/7e1fa4d8z5408z419bz9394z19ae17697026
Development of a flow cytometry method to measure antidrug antibodies against CAR T cells
Day, G., Sánchez-Martín, F. J., Seavers, L., Cadwallader, K. A., & Morgado-García, S. (2026) · ImmunoHorizons · doi:10.1093/immhor/vlag011
Leveraging the bacteria for enhanced cancer immunotherapy: from a perspective of synthetic biology
Liu, X., Zhang, H., Du, R., Liu, Z., Ren, Y., & Yang, X. S. (2026) · Cancer Biology & Therapy · doi:10.1080/15384047.2026.2683171 · Cited by 1
Celyvir: Oncolytic Virotherapy with Mesenchymal Stromal Cells. From Concept to Clinical Translation
Morales‐Molina, Á., & García-Castro, J. (2026) · Human Gene Therapy · doi:10.1177/10430342261437962
Hu, S., Shi, G., Zhao, J., Long, X., Tang, L., Qi, Z., Xu, X., Cheng, P., & Liu, J. (2026) · Molecular Therapy · doi:10.1016/j.ymthe.2026.08.021 · Cited by 1
Modulating gut microbiome in cancer immunotherapy: Harnessing microbes to enhance treatment efficacy
Mishra, A., & Sahu, S. K. (2026) · Elsevier eBooks · doi:10.1016/b978-0-443-33206-7.00013-3
Cancer Immunotherapy and Immune-Related Adverse Events: Focusing on Non-Small Cell Lung Cancer
Kamil, A., Cowles, S., Driver, C. C., Arora, A., Swyers, M. M., Boldt, L. W., Muzaffar, M., Batoo, S. A., & Yang, L. V. (2026) · Current Oncology · doi:10.3390/curroncol33100607
“This pioneering work provided proof of concept for immunotherapy, but unknown mechanisms, variable results, and infection risks deterred the progress [7,8].”
Radioimmunotherapy: Mechanisms, Strategies, and Advances in Therapeutic Enhancement
Naqvi, S. A. R., Fatima, S. M., Waji-Ul-Hassan, S. M., Gursal, S. A., Fatima, S., Imran, M. B., Wasim, M., Ramadan, M. F., & Lodhi, N. A. (2026) · Cancer Biotherapy and Radiopharmaceuticals · doi:10.1177/10849785261486288
Cyclin B1: Abnormal Self /Tumor Antigen
Vella, L. A. (2008) · D-Scholarship@Pitt (University of Pittsburgh)
Metadata
- Authors
- Starnes, C. O.
- Affiliations
- Amgen (United States) (US)
- Corresponding author
- Starnes, Charlie O.
- Venue
- Nature
- Published
- 1992-05
- Volume
- 357
- Issue
- 6373
- Pages
- 11-12
- ISSN
- 0028-0836 (ISSN-L)
- 1476-4687
- OpenAlex
- W2005179058
- Cited by
- 284
- References
- 6
- Citations by year
- 2026: 14 · 2025: 15 · 2024: 34 · 2023: 14 · 2022: 14 · 2021: 19 · 2020: 17 · 2019: 9 · 2018: 11 · 2017: 12 · 2016: 7 · 2015: 15 · 2014: 8 · 2013: 9 · 2012: 7
- FWCI
- 2.07
- Type
- journal article
- Language
- en
- Open access
- closed
- Licence
- www.springer.com/tdm (tdm)
- Locations
- Nature (publishedVersion)
- PubMed (publishedVersion)
- Topics
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Biotechnology › Bacterial Cancer Therapy
- Life Sciences › Immunology and Microbiology › Immunology › Immunotherapy and Immune Responses
- Health Sciences › Medicine › Pharmacology (medical) › Historical Medical Research and Treatments
- Keywords
- Coley's toxins, TNF-α, cancer therapy, patient selection, treatment efficacy
- MeSH terms
- Bacterial Vaccines, Humans, Sarcoma, Soft Tissue Neoplasms, Tumor Necrosis Factor-alpha, History, 19th Century, History, 20th Century
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.